Phase 1 Trial of ADI PEG 20 Plus Docetaxel in Advanced Solid Tumors With Emphasis on Castration Resistant Prostate Cancer (CRPC) and Advanced Non-Small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Pegargiminase (Primary) ; Docetaxel
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Polaris Pharmaceuticals
- 03 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 May 2017.
- 03 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2017.
- 25 Jan 2017 Planned End Date changed from 1 Oct 2016 to 1 Mar 2017.